The role of helper T cells in psoriasis
P Hu, M Wang, H Gao, A Zheng, J Li, D Mu… - Frontiers in …, 2021 - frontiersin.org
Psoriasis is a complex, chronic relapsing and inflammatory skin disorder with a prevalence
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …
of approximately 2% in the general population worldwide. Psoriasis can be triggered by …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …
manifestations, or both, and it has a major impact on quality of life. Although there is …
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase …
Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …
(IL)-17F in addition to IL-17A. This study investigated the efficacy and safety of bimekizumab …
The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications
Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis
involves the dysregulation of the immune system. The interplay among cytokines released …
involves the dysregulation of the immune system. The interplay among cytokines released …
Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review
Psoriasis is a common inflammatory skin disease with multiple comorbidities, including
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …
psoriatic arthritis and coronary artery disease, that can severely impact an individual's …
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
Background Guselkumab, tildrakizumab, and risankizumab, acting on interleukin (IL) 23
axis, have been recently approved for psoriasis management. However, real-life data …
axis, have been recently approved for psoriasis management. However, real-life data …
Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies
Psoriasis is a common chronic inflammatory skin disease, associated with substantial
comorbidity. TH17 lymphocytes, differentiating under the influence of dendritic cell-derived …
comorbidity. TH17 lymphocytes, differentiating under the influence of dendritic cell-derived …
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study
Background Drug survival analysis of biologic agents in psoriasis is of extreme importance,
as it allows not only the evaluation of objective clinical outcomes (such as effectiveness and …
as it allows not only the evaluation of objective clinical outcomes (such as effectiveness and …
Biologic treatments of psoriasis: an update for the clinician
ND Brownstone, J Hong, M Mosca… - … : Targets and Therapy, 2021 - Taylor & Francis
The advent of biologic agents within the past two decades has dramatically improved the
treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved …
treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved …
Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review
A Thatiparthi, A Martin, J Liu, A Egeberg… - American Journal of …, 2021 - Springer
The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …
our improved understanding of psoriasis pathogenesis have increased the therapeutic …